Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | MITF | O75030 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3931762 | 0.88 | KMT2A (0.52) | KMT2AMEN1SMN1; SMN2MITFALDH1A1 | |
| SCHEMBL8316562 | 0.87 | KMT2A (0.62) | KMT2AMEN1SMN1; SMN2MITFALDH1A1 | |
| SCHEMBL11684508 | 0.85 | MEN1 (0.74) | KMT2AMEN1MITFALDH1A1KDM4E | |
| SCHEMBL11684541 | 0.85 | MEN1 (0.74) | KMT2AMEN1MITFALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL11685219 | 0.84 | MEN1 (0.73) | KMT2AMEN1MITFALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL11685544 | 0.84 | MEN1 (0.73) | KMT2AMEN1MITFALDH1A1KDM4E | |
| SCHEMBL696157 | 0.84 | MEN1 (0.64) | KMT2AMEN1ALDH1A1KDM4EPOLB | |
| SCHEMBL89815 | 0.80 | MEN1 (0.54) | KMT2AMEN1SMN1; SMN2ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL11684516 | 0.80 | KMT2A (0.58) | KMT2AMEN1SMN1; SMN2MITFALDH1A1 | |
| SCHEMBL17099881 | 0.78 | KMT2A (0.52) | KMT2AMEN1SMN1; SMN2MITFALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124691-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | KELLEHER JUDITH A (US) | 2005-06-09 | — | — | US | disclosed |
| EP-1025079-B1 | $g(a)-ARYL-$i(N)-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | RENOVIS INC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20030087957-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | RENOVIS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6441032-B1 | TREATING SYSTEMIC LUPIS AND MULTIPLE SCLEROSIS | CENTAUR PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | disclosed |
| US-6433008-B1 | TREATING PARKINSON*S, ALZHEIMER*S, AUTOIMMUNE AND RHEUMATIC DISEASES; HUMAN IMMUNODEFICIENCY VIRUS (HIV) DEMENTIA, AND INFLAMMATION | CENTAUR PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| EP-1025079-A1 | $g(a)-ARYL-$i(N)-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-08-09 | — | — | EP | disclosed |
| US-6046232-A | THERAPEUTICS FOR TREATING AND/OR PREVENTING NEUROLOGICAL, AUTOIMMUNE AND INFLAMMATORY CONDITIONS IN MAMMALS AND AS ANALYTICAL REAGENTS FOR DETECTING FREE RADICALS | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-04-04 | — | — | US | disclosed |
| WO-1999020601-A1 | α-ARYL-N-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124691-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | NLN, NAT1, SNCA | KMT2A 4081/4885MEN1 2880/4885SMN1; SMN2 184/4885 |
| US-20030087957-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | NLN, NAT1, SNCA | KMT2A 3999/4885MEN1 3044/4885SMN1; SMN2 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.